Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10). Read more about Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Accuracy, readability, and quality of websites about metastatic renal cell carcinoma treatment. Read more about Accuracy, readability, and quality of websites about metastatic renal cell carcinoma treatment.
Evaluation of URO17® to improve non-invasive detection of bladder cancer. Read more about Evaluation of URO17® to improve non-invasive detection of bladder cancer.
Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era. Read more about Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era.
Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Read more about Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life.
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab. Read more about Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer. Read more about Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer.
Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols. Read more about Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols.
The costs and inequities of precision medicine for patients with prostate cancer: A call to action. Read more about The costs and inequities of precision medicine for patients with prostate cancer: A call to action.
Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Read more about Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.
